Guard Therapeutics International AB is a pharmaceutical company, which engages in the research, development, and commercialization of medical treatment and diagnosis based on alpha-1-microglobulin. It focuses on the treatment of pre-eclampsia and acute kidney injury. The company was founded by Bo Åkerström, Tomas Jörgen Eriksson, Stefan Hansson, Gram Magnus on April 4, 2008 and is headquartered in Stockholm, Sweden.